Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results.
We evaluated immunogenicity and reactogenicity of an inactivated, combined hepatitis A/B candidate vaccine in 50 seronegative volunteers. Each volunteer received a total of three doses of vaccine (720 EIU HAV and 20 micrograms HBs antigen) according to a 0, 1 and 6 month vaccination schedule. One month after the first injection, the seroconversion rate was 90% (45/50) for anti-HAV and 28% (14/50) for anti-HBs, respectively. After the booster dose, at month 7, the seroconversion rate was as high as 100% (49/49) for anti-HAV and 94% (46/49) for anti-HBs. The geometric mean titres increased with each dose of vaccine administered. Mild, and mostly local side effects were reported in 54% of the volunteers after the first injection and in less than 10% after the third injection. Our results show that this inactivated, candidate hepatitis A/B vaccine is highly immunogenic and well-tolerated.
Kallinowski
B
B
University Hospital of Heidelberg, Germany.
Bock
H L
HL
Clemens
R
R
Theilmann
L
L
D000328:Adult; D000906:Antibodies / Q000097:blood / Q000276:immunology / Q000378:metabolism; D003625:Data Collection; D005260:Female; D005858:Germany; D006506:Hepatitis A / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012699:Serology; D012907:Smoking; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D000906:Antibodies; D014761:Viral Hepatitis Vaccines